Aclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis (AD)
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Aclaris Therapeutics (ACRS) reported that its Phase 2 ADMIRATION trial of bosakitug in moderate-to-severe atopic dermatitis missed its primary and secondary endpoints. The primary endpoint measured the percentage change from baseline in Eczema Area and Severity Index score at week 24. Biological measurements showed TSLP target engagement and reductions in biomarkers linked to immune activation. Bosakitug was generally well tolerated.
Aclaris said its development priorities remain oral kinase inhibitors and the bispecific antibody ATI-052. It has initiated a Phase 2b trial of modzatinib in lichen planus and completed studies supporting an investigational new drug application for ATI-9494. The company expects to file that application this quarter and intends to initiate a Phase 2b trial of ATI-052 in eosinophilic esophagitis in the first quarter of 2027.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointModzatinib Phase 2b trial initiated in lichen planus.
- Minor pointBosakitug showed TSLP target engagement and reduced immune-activation biomarkers, including Th1, Th2, and Th17.
- Minor pointBosakitug was generally well tolerated in the Phase 2 ADMIRATION trial.
- Minor point. Forward-looking: it has not happened yet and may not happen.ATI-9494 application-supporting studies completed; Aclaris expects to file its investigational new drug application this quarter.
- Minor point. Forward-looking: it has not happened yet and may not happen.ATI-052 Phase 2b trial in eosinophilic esophagitis is planned for the first quarter of 2027.
Negative
- Major pointBosakitug's Phase 2 ADMIRATION trial missed primary and secondary endpoints in moderate-to-severe atopic dermatitis.
Key Figures
- Primary endpoint assessment
- Week 24
- Percent change in EASI score from baseline; endpoint not achieved
Previous Clinical trial Reports
-
Earlier enrollment set 109 patients and the Week 24 EASI endpoint for this bosakitug trial.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
easi medical
pharmacodynamic medical
tslp medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- The ADMIRATION Trial Did Not Achieve its Primary Endpoint of Percent Change in Eczema Area and Severity Index (EASI) Score from Baseline at Week 24 -
- Aclaris Remains Focused on Prioritizing the Development of its Oral Kinase (ITK) Inhibitors and Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 -
WAYNE, Pa., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced top line results from the Phase 2 ADMIRATION trial that evaluated the efficacy and safety of bosakitug (ATI-045), a humanized anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody, in patients with moderate-to-severe atopic dermatitis. The trial did not achieve the primary or secondary endpoints; however, pharmacodynamic (PD) results showed robust target engagement of TSLP and downregulation of biomarkers related to immune activation including Th1, Th2, and Th17. Bosakitug was generally well tolerated in this trial.
“We are disappointed that the ADMIRATION trial did not overcome the historical challenges of addressing atopic dermatitis with an anti-TSLP monoclonal antibody alone,” said Dr. Neal Walker, Chief Executive Officer of Aclaris. “We are grateful to the patients and investigators whose participation and commitment made this study possible.”
Dr. Walker continued, “These results do not change our development priorities, which remain focused on our oral kinase inhibitors and anti-TSLP/IL-4Rα bispecific antibody ATI-052. First and foremost, we have initiated the Phase 2b trial of our oral ITK/JAK3 inhibitor modzatinib in lichen planus. We’ve also completed the IND-enabling studies for our oral ITK inhibitor ATI-9494 and expect to file the IND this quarter. Lastly, we intend to initiate the Phase 2b trial with ATI-052 in eosinophilic esophagitis in the first quarter of 2027. We expect to achieve numerous important regulatory, clinical, and data milestones throughout 2027 with each of these assets.”
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Aclaris’ current beliefs and expectations. These forward-looking statements include expectations regarding its development plans and expected milestones for ATI-052, modzatinib and ATI-9494, including the timing to initiate its Phase 2b trial of ATI-052 in eosinophilic esophagitis, and the timing to submit the IND for ATI-9494. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, risks associated with interim, top line and preliminary data, Aclaris’ reliance on third parties over which it may not always have full control, Aclaris’ ability to enter into strategic partnerships on commercially reasonable terms, the uncertainty regarding the macroeconomic environment and other risks and uncertainties that are described in the Risk Factors section of Aclaris’ Annual Report on Form 10-K for the year ended December 31, 2025, and other filings Aclaris makes with the U.S. Securities and Exchange Commission from time to time. These documents are available under the “SEC Filings” page of the “Investors” section of Aclaris’ website at www.aclaristx.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to Aclaris as of the date of this release, and Aclaris assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
Aclaris Therapeutics Contact:
Will Roberts
Senior Vice President
Corporate Communications and Investor Relations
(484) 329-2125
wroberts@aclaristx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.